• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Whitmore R Janet bought $63,274 worth of shares (35,056 units at $1.80), increasing direct ownership by 2% to 2,084,198 units (SEC Form 4)

    12/11/25 11:50:36 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $SLSN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    WHITMORE R JANET

    (Last) (First) (Middle)
    1319 MARQUETTE DRIVE

    (Street)
    ROMEOVILLE IL 60446

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SOLESENCE, INC. [ SLSN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 2,049,142 D
    Common Stock 11/14/2025 11/14/2025 P 19,789 A $1.73 2,068,931 D
    Common Stock 11/17/2025 11/17/2025 P 5,000 A $1.87 2,073,931 D
    Common Stock 11/18/2025 11/18/2025 P 267 A $1.83 2,074,198 D
    Common Stock 11/19/2025 11/19/2025 P 5,000 A $1.95 2,079,198 D
    Common Stock 11/19/2025 11/19/2025 P 5,000 A $1.89 2,084,198 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Deferred Common Stock (1) (2) (2)(3) Common Stock 20,030 20,030 D
    Common Stock (right to purchase) $1.85(4) 11/17/2016 11/17/2026 Common Stock 2,000 2,000 D
    Common Stock (right to purchase) $4.17 12/28/2022(5) 12/28/2028 Common Stock 20,000 20,000 D
    Common Stock (right to purchase) $1.165 12/20/2023(5) 12/20/2029 Common Stock 13,334 13,334 D
    Common Stock (right to purchase) $0.61 12/27/2024(5) 12/27/2030 Common Stock 12,600 12,600 D
    Common Stock (Right to Buy) $2.44 12/31/2025(5) 12/31/2031 Common Stock 12,000 12,000 D
    Explanation of Responses:
    1. Each share of deferred common stock represents the right to receive one share of common stock.
    2. The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.
    3. Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensaion Plan.
    4. The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. These 2000 shares were issued with an exercise price of $1.85.
    5. Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
    Remarks:
    Due to administrative issues relating to establishing Ms. Whitmore's account with Edgar Next this filing was delayed.
    /s/ Laura Riffner, Under UPA for R. Janet Whitmore 12/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SLSN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLSN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SLSN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solésence Reports Third Quarter 2025 Financial Results

    Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2025. Recent Highlights and Accomplishments Continued strategic transformation to drive future innovation and growth with promotion of Kevin Cureton to President and Chief Executive Officer.Appointed Laura Riffner, a seasoned financial and operations expert, as Chief Financial Officer to lead accounting and finan

    11/11/25 7:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence, Inc. Appoints Yoana Dvorzsak as Vice President of Innovation and Product Integrity

    Dvorzsak to oversee product quality and drive innovation to support growth amidst evolving consumer needs; Named a Cosmetic Executive Women (CEW) Innovator Honoree ROMEOVILLE, Ill., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoana Dvorzsak to the newly created role of Vice President of Innovation and Product Integrity to support the Company's continued innovation and operational excellence in its new phase of growth. Dvorzsak will lead a newly unified group that combines Solésence's research and development, product and component de

    11/10/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence To Report Third Quarter 2025 Financial Results and Host a Conference Call

    ROMEOVILLE, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the third quarter of 2025 before the market opens on Tuesday, November 11, 2025, and host a conference call and webcast on the same date. Third Quarter 2025 Conference Call DetailsDate / Time: Tuesday, November 11, 2025 – 7:30 a.m. CDT, 8:30 a.m. EDT Speakers: Kevin Cureton, President & CEO, Laura Riffner, Chief Financial Officer, and Jess Jankowski, Board Advisor Webcast Link: https://edge.media-server.com/mmc/p/qur8mp24 Dial-In Link: https://registe

    10/30/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Whitmore R Janet bought $63,274 worth of shares (35,056 units at $1.80), increasing direct ownership by 2% to 2,084,198 units (SEC Form 4)

    4 - SOLESENCE, INC. (0000883107) (Issuer)

    12/11/25 11:50:36 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Riffner Laura C

    3 - SOLESENCE, INC. (0000883107) (Issuer)

    10/6/25 10:07:15 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Operating Officer Cureton Kevin exercised 43,500 shares at a strike of $0.42 and sold $166,051 worth of shares (43,500 units at $3.82) (SEC Form 4)

    4 - SOLESENCE, INC. (0000883107) (Issuer)

    6/6/25 7:00:04 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    SEC Filings

    View All

    Solesence Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - SOLESENCE, INC. (0000883107) (Filer)

    12/2/25 7:11:43 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solesence Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - SOLESENCE, INC. (0000883107) (Filer)

    12/1/25 12:23:33 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solesence Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SOLESENCE, INC. (0000883107) (Filer)

    11/12/25 7:30:28 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Whitmore R Janet bought $63,274 worth of shares (35,056 units at $1.80), increasing direct ownership by 2% to 2,084,198 units (SEC Form 4)

    4 - SOLESENCE, INC. (0000883107) (Issuer)

    12/11/25 11:50:36 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Large owner Whitmore Bradford T bought $28,093,800 worth of shares (6,689,000 units at $4.20) and sold $28,093,800 worth of shares (6,689,000 units at $4.20) (SEC Form 4)

    4 - SOLESENCE, INC. (0000883107) (Issuer)

    6/2/25 4:01:15 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    Leadership Updates

    Live Leadership Updates

    View All

    Solésence, Inc. Appoints Yoana Dvorzsak as Vice President of Innovation and Product Integrity

    Dvorzsak to oversee product quality and drive innovation to support growth amidst evolving consumer needs; Named a Cosmetic Executive Women (CEW) Innovator Honoree ROMEOVILLE, Ill., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoana Dvorzsak to the newly created role of Vice President of Innovation and Product Integrity to support the Company's continued innovation and operational excellence in its new phase of growth. Dvorzsak will lead a newly unified group that combines Solésence's research and development, product and component de

    11/10/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth

    ROMEOVILLE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company's expansion and innovation, will assume the role of President and Chief Executive Officer. Laura Riffner has been appointed Chief Financial Officer, bringing decades of financial expertise in enhancing operational excellence and efficiency. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company

    9/3/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence to Join Russell 3000® and Russell 2000® Indexes

    ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be added as a member of the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or

    6/24/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    $SLSN
    Financials

    Live finance-specific insights

    View All

    Solésence Reports Third Quarter 2025 Financial Results

    Advances Strategic Transformation with Key Changes in Executive Leadership, Product Development and Operations ROMEOVILLE, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2025. Recent Highlights and Accomplishments Continued strategic transformation to drive future innovation and growth with promotion of Kevin Cureton to President and Chief Executive Officer.Appointed Laura Riffner, a seasoned financial and operations expert, as Chief Financial Officer to lead accounting and finan

    11/11/25 7:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence To Report Third Quarter 2025 Financial Results and Host a Conference Call

    ROMEOVILLE, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the third quarter of 2025 before the market opens on Tuesday, November 11, 2025, and host a conference call and webcast on the same date. Third Quarter 2025 Conference Call DetailsDate / Time: Tuesday, November 11, 2025 – 7:30 a.m. CDT, 8:30 a.m. EDT Speakers: Kevin Cureton, President & CEO, Laura Riffner, Chief Financial Officer, and Jess Jankowski, Board Advisor Webcast Link: https://edge.media-server.com/mmc/p/qur8mp24 Dial-In Link: https://registe

    10/30/25 8:00:00 AM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary

    Solésence Reports Second Quarter 2025 Financial Results

    ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025.    Recent Highlights and Accomplishments Joined broad-market Russell 3000® and small-cap Russell 2000® IndexesAmended loan agreements to fuel growth initiatives "During our seasonally highest-performing quarter, we're pleased with the effectiveness of our commercial execution and the consistent, on-time delivery of products to our partners," said Jess Jankowski, President and Chief Executive Officer of Solésence. "Innovation

    7/31/25 4:01:00 PM ET
    $SLSN
    Package Goods/Cosmetics
    Consumer Discretionary